Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Cardio-oncology: what you need to know now for clinical practice and echocardiography.

Larsen CM, Mulvagh SL.

Echo Res Pract. 2017 Mar;4(1):R33-R41. doi: 10.1530/ERP-17-0013. Epub 2017 Mar 2. Review.

2.

Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.

Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC.

J Breast Cancer. 2016 Dec;19(4):402-409. doi: 10.4048/jbc.2016.19.4.402. Epub 2016 Dec 23.

3.

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.

Chung WB, Youn HJ.

Korean J Intern Med. 2016 Jul;31(4):625-33. doi: 10.3904/kjim.2016.017. Epub 2016 Jul 1. Review.

4.

Cardiac dysfunction among soft tissue sarcoma patients in Denmark.

Shantakumar S, Olsen M, Vo TT, Nørgaard M, Pedersen L.

Clin Epidemiol. 2016 Apr 15;8:53-9. doi: 10.2147/CLEP.S100779. eCollection 2016.

5.

Cardio-oncology: Concepts and practice.

Cubbon RM, Lyon AR.

Indian Heart J. 2016 Apr;68 Suppl 1:S77-85. doi: 10.1016/j.ihj.2016.01.022. Epub 2016 Feb 11. Review.

6.

Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.

Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, De Placido S, Bonaduce D, Tocchetti CG.

Biomed Res Int. 2015;2015:138148. doi: 10.1155/2015/138148. Epub 2015 Oct 25. Review.

7.

Risk factors for anthracycline-associated cardiotoxicity.

Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2016 May;24(5):2173-2180. doi: 10.1007/s00520-015-3008-y. Epub 2015 Nov 12.

8.

Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.

Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, Iliescu C, Ky B, Mayer EL, Okwuosa TM, Plana JC, Ryan TD, Rzeszut AK, Douglas PS.

J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46. doi: 10.1016/j.jacc.2015.04.059. Review.

9.

Lack of an association between angiotensin receptor blocker based therapy and increased risk of cancer: evidence from large observational studies.

Yang Y, Zhang F, Skrip L, Lei H, Luo S, Lu K, Hu D.

PLoS One. 2015 Mar 19;10(3):e0119775. doi: 10.1371/journal.pone.0119775. eCollection 2015.

10.

Intersection of cardiology and oncology clinical practices.

Mookadam F, Sharma A, Lee HR, Northfelt DW.

Front Oncol. 2014 Sep 24;4:259. doi: 10.3389/fonc.2014.00259. eCollection 2014. Review. No abstract available.

11.

Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury.

Cross MJ, Berridge BR, Clements PJ, Cove-Smith L, Force TL, Hoffmann P, Holbrook M, Lyon AR, Mellor HR, Norris AA, Pirmohamed M, Tugwood JD, Sidaway JE, Park BK.

Br J Pharmacol. 2015 Feb;172(4):957-74. doi: 10.1111/bph.12979. Epub 2015 Jan 12. Review.

12.

Contemporary strategies in the diagnosis and management of heart failure.

Dunlay SM, Pereira NL, Kushwaha SS.

Mayo Clin Proc. 2014 May;89(5):662-76. doi: 10.1016/j.mayocp.2014.01.004. Epub 2014 Mar 29. Review.

13.

The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer.

Sturgeon KM, Ky B, Libonati JR, Schmitz KH.

Breast Cancer Res Treat. 2014 Jan;143(2):219-26. doi: 10.1007/s10549-013-2808-3. Epub 2013 Dec 14. Review.

14.

Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer.

Chung WB, Yi JE, Jin JY, Choi YS, Park CS, Park WC, Song BJ, Youn HJ.

J Breast Cancer. 2013 Jun;16(2):178-83. doi: 10.4048/jbc.2013.16.2.178. Epub 2013 Jun 28.

15.

Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy?

Haberland A, Santos RA, Schimke I, Wallukat G.

Case Rep Oncol. 2013 Jan;6(1):104-8. doi: 10.1159/000348425. Epub 2013 Feb 21.

16.

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.

Jensen BC, McLeod HL.

Pharmacogenomics. 2013 Jan;14(2):205-13. doi: 10.2217/pgs.12.205. Review.

17.

Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.

Knobf MT, Coviello J.

Curr Cardiol Rev. 2011 Nov;7(4):250-7. Review.

18.

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.

Volkova M, Russell R 3rd.

Curr Cardiol Rev. 2011 Nov;7(4):214-20. Review.

19.

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.

Jiji RS, Kramer CM, Salerno M.

J Nucl Cardiol. 2012 Apr;19(2):377-88. doi: 10.1007/s12350-012-9512-2. Review.

Supplemental Content

Support Center